ArticleOncoTargets and therapy2019

Synergistic effect of a retinoid X receptor-selective ligand bexarotene and docetaxel in prostate cancer.

Danyang Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.